37.56
前日終値:
$37.15
開ける:
$37.68
24時間の取引高:
3.68M
Relative Volume:
0.69
時価総額:
$76.68B
収益:
$40.95B
当期純損益:
$4.43B
株価収益率:
17.50
EPS:
2.1468
ネットキャッシュフロー:
$6.10B
1週間 パフォーマンス:
-1.08%
1か月 パフォーマンス:
-3.57%
6か月 パフォーマンス:
+6.49%
1年 パフォーマンス:
-5.25%
Gsk Plc Adr Stock (GSK) Company Profile
GSK を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
GSK
Gsk Plc Adr
|
37.56 | 74.96B | 40.95B | 4.43B | 6.10B | 2.1468 |
![]()
LLY
Lilly Eli Co
|
762.33 | 664.39B | 49.00B | 11.11B | -1.27B | 12.29 |
![]()
JNJ
Johnson Johnson
|
167.33 | 396.75B | 90.63B | 22.66B | 16.40B | 9.35 |
![]()
ABBV
Abbvie Inc
|
195.22 | 333.89B | 58.33B | 3.76B | 15.39B | 2.10 |
![]()
NVS
Novartis Ag Adr
|
115.30 | 220.18B | 55.19B | 13.65B | 16.81B | 6.86 |
![]()
MRK
Merck Co Inc
|
79.29 | 196.16B | 63.62B | 16.41B | 17.04B | 6.49 |
Gsk Plc Adr Stock (GSK) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-06-03 | ダウングレード | Berenberg | Buy → Hold |
2025-04-15 | 開始されました | Exane BNP Paribas | Neutral |
2025-02-12 | 開始されました | Morgan Stanley | Equal-Weight |
2024-11-15 | ダウングレード | Deutsche Bank | Buy → Hold |
2024-11-12 | ダウングレード | Jefferies | Buy → Hold |
2024-10-31 | ダウングレード | Guggenheim | Buy → Neutral |
2024-07-08 | ダウングレード | UBS | Buy → Neutral |
2024-05-30 | 開始されました | Goldman | Neutral |
2024-03-04 | アップグレード | Guggenheim | Neutral → Buy |
2024-02-13 | アップグレード | Citigroup | Neutral → Buy |
2024-01-23 | 開始されました | Morgan Stanley | Equal-Weight |
2024-01-16 | 再開されました | UBS | Buy |
2024-01-03 | アップグレード | Jefferies | Hold → Buy |
2023-07-14 | 開始されました | HSBC Securities | Reduce |
2023-03-17 | アップグレード | Deutsche Bank | Hold → Buy |
2023-02-27 | 再開されました | Goldman | Buy |
2023-01-03 | ダウングレード | JP Morgan | Neutral → Underweight |
2022-12-05 | ダウングレード | BofA Securities | Neutral → Underperform |
2022-11-11 | ダウングレード | UBS | Neutral → Sell |
2022-09-15 | アップグレード | Credit Suisse | Underperform → Neutral |
2022-09-08 | ダウングレード | Jefferies | Buy → Hold |
2022-08-05 | 再開されました | Morgan Stanley | Equal-Weight |
2022-07-21 | 再開されました | Citigroup | Neutral |
2022-02-11 | ダウングレード | DZ Bank | Buy → Hold |
2021-11-05 | アップグレード | Barclays | Underweight → Equal Weight |
2021-06-24 | アップグレード | Deutsche Bank | Sell → Hold |
2021-03-23 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
2021-02-04 | ダウングレード | Deutsche Bank | Hold → Sell |
2021-01-20 | ダウングレード | Credit Suisse | Neutral → Underperform |
2021-01-15 | 開始されました | Deutsche Bank | Hold |
2020-11-02 | アップグレード | Liberum | Hold → Buy |
2020-09-29 | 開始されました | Berenberg | Buy |
2020-02-12 | ダウングレード | Shore Capital | Hold → Sell |
2020-01-16 | ダウングレード | Barclays | Equal Weight → Underweight |
2019-12-02 | 開始されました | SVB Leerink | Outperform |
2019-11-21 | アップグレード | UBS | Neutral → Buy |
2019-10-11 | アップグレード | Cantor Fitzgerald | Hold → Buy |
2019-09-03 | 再開されました | Citigroup | Neutral |
2019-09-03 | アップグレード | Societe Generale | Sell → Buy |
2019-08-13 | 再開されました | JP Morgan | Neutral |
2019-06-17 | 再開されました | Morgan Stanley | Underweight |
2019-03-08 | ダウングレード | Shore Capital | Buy → Hold |
2019-02-22 | ダウングレード | UBS | Buy → Neutral |
2019-01-14 | ダウングレード | Exane BNP Paribas | Outperform → Neutral |
2018-12-11 | 再開されました | Jefferies | Buy |
2018-10-09 | 開始されました | Guggenheim | Neutral |
2018-08-30 | ダウングレード | Liberum | Buy → Hold |
2018-04-04 | アップグレード | Exane BNP Paribas | Neutral → Outperform |
2018-03-22 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
2018-02-09 | アップグレード | Kepler | Reduce → Hold |
すべてを表示
Gsk Plc Adr (GSK) 最新ニュース
Pharma Stocks Slump on Presidential Ultimatum To Cut Prices - Morningstar
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK - GlobeNewswire Inc.
Company News for Jul 31, 2025 - The Globe and Mail
GSK Beats on Q2 Earnings & Sales, Stock Gains on '25 Outlook Raise - TradingView
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
GSK Plc ADR (GSK) Stock: A Year of Stock Market Dynamics - investchronicle.com
Fifth Third Bancorp Inc. (FITB) Price Performance Over the Years: A Comparative Study - investchronicle.com
Navigating YMM Stock: Full Truck Alliance Co Ltd ADR Journey - investchronicle.com
GDS Holdings Limited ADR (GDS) Stock: Navigating a Year of Volatility - investchronicle.com
The Future of Microvast Holdings Inc: Analyzing MVST - investchronicle.com
SES AI Corporation (SES) Stock: Exploring a Year of Highs, Lows, and Trading Volume - investchronicle.com
SKYQ’s Stock Woes: Down -53.24% in 6 Months, Down -53.24% in Just 5 Days - investchronicle.com
Antero Resources Corp (AR) Stock: A Year of Declines and Increases - investchronicle.com
The Psychology of HUYA Inc ADR Inc. (HUYA) Price Performance: Understanding Market Sentiment - investchronicle.com
American Resources Corporation: Analyzing AREC Stock Trends - investchronicle.com
MSP Recovery Inc (MSPR) Stock: Navigating a Year of Stock Volatility - investchronicle.com
Coty Inc (COTY) Stock: A Year of Highs and Lows in the Market - investchronicle.com
Behind Palladyne AI Corp’s 52-Week Range: Uncovering Opportunities for Investors - investchronicle.com
NVO’s 2025 Market Dance: Down -51.70% – Time to Invest? - investchronicle.com
Celularity Inc (CELU) Stock: A Year of Market Fluctuations - investchronicle.com
Bilibili Inc ADR (BILI) Stock: Uncovering 52-Week Market Trends - investchronicle.com
Captivision Inc Inc. (CAPT) Price Performance: The Role of Supply and Demand - investchronicle.com
Charting the Course: Castellum Inc’s CTM Stock Prospects - investchronicle.com
MBIO Stock: Exploring Mustang Bio Inc’s Growth - investchronicle.com
IBG’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - investchronicle.com
IBIO’s Market Whiplash: -61.36% YTD Decline, -20.36% Plunge in 30 Days - investchronicle.com
LQR House Inc (YHC) Stock: A Year of Stock Market Dynamics - investchronicle.com
INKT’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
Crossmark Global Holdings Inc. Reduces Stock Holdings in ARM Holdings PLC Sponsored ADR (NASDAQ:ARM) - Defense World
FDA Accepts GSK Filing for Expanded Use of RSV Shot in Younger Adults - The Globe and Mail
FDA Accepts GSK Filing For Expanded Use Of RSV Shot In Younger Adults - Barchart.com
Argentina Lithium & Energy (CVE:LIT) Shares Down 12.5% – What’s Next? - Defense World
Brown Advisory Inc. Increases Holdings in Invesco BulletShares 2026 Corporate Bond ETF (NASDAQ:BSCQ) - Defense World
Callan Capital LLC Raises Stock Holdings in Alphabet Inc. (NASDAQ:GOOGL) - Defense World
Brown Advisory Inc. Boosts Position in Schwab US Large-Cap ETF (NYSEARCA:SCHX) - Defense World
KBR, Inc. (NYSE:KBR) Holdings Trimmed by M&T Bank Corp - Defense World
Invesco RAFI Developed Markets ex-U.S. ETF (NYSEARCA:PXF) Position Increased by Bank of New York Mellon Corp - Defense World
Verisk Analytics, Inc. (NASDAQ:VRSK) Shares Sold by Stratos Wealth Partners LTD. - Defense World
Post Resch Tallon Group Inc. Has $818,000 Stock Position in NVIDIA Corporation (NASDAQ:NVDA) - Defense World
Alphabet Inc. (NASDAQ:GOOGL) Shares Purchased by Interchange Capital Partners LLC - Defense World
Crossmark Global Holdings Inc. Purchases New Stake in Cushman & Wakefield PLC (NYSE:CWK) - Defense World
4,270 Shares in iShares California Muni Bond ETF (NYSEARCA:CMF) Bought by Crossmark Global Holdings Inc. - Defense World
Wall Street Zen Upgrades LCI Industries (NYSE:LCII) to Buy - Defense World
Citigroup Forecasts Strong Price Appreciation for Establishment Labs (NASDAQ:ESTA) Stock - Defense World
Is Your Investment Portfolio Ready for a US-EU Trade Deal? - Morningstar
Amalgamated Bank Sells 311 Shares of Benchmark Electronics, Inc. (NYSE:BHE) - Defense World
Amalgamated Bank Has $429,000 Stock Position in NetScout Systems, Inc. (NASDAQ:NTCT) - Defense World
Amalgamated Bank Trims Stock Position in National Bank Holdings Corporation (NYSE:NBHC) - Defense World
The 10 Best Companies to Invest in Now - Morningstar
GENFIT (NASDAQ:GNFT) Shares Up 0.7% – Time to Buy? - Defense World
LyondellBasell Industries NV (LYB) Stock: Navigating Market Highs and Lows in 52 Weeks - investchronicle.com
Gsk Plc Adr (GSK) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):